Nadine Jackson McCleary, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colonic Neoplasms | 10 | 2022 | 2544 | 1.590 |
Why?
|
Colorectal Neoplasms | 15 | 2024 | 6978 | 1.280 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 959 | 0.970 |
Why?
|
Rectal Neoplasms | 3 | 2022 | 1179 | 0.940 |
Why?
|
Fluorouracil | 8 | 2022 | 1656 | 0.860 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11843 | 0.770 |
Why?
|
Cancer Care Facilities | 2 | 2024 | 424 | 0.690 |
Why?
|
Geriatric Assessment | 4 | 2017 | 1422 | 0.630 |
Why?
|
Electronic Health Records | 6 | 2024 | 4877 | 0.630 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2018 | 876 | 0.620 |
Why?
|
Mouth Neoplasms | 1 | 2023 | 598 | 0.600 |
Why?
|
Chemotherapy, Adjuvant | 10 | 2022 | 3550 | 0.600 |
Why?
|
Early Termination of Clinical Trials | 1 | 2017 | 70 | 0.570 |
Why?
|
Self-Help Groups | 1 | 2018 | 193 | 0.560 |
Why?
|
Camptothecin | 5 | 2022 | 594 | 0.530 |
Why?
|
Adenocarcinoma | 7 | 2024 | 6400 | 0.440 |
Why?
|
Bone Marrow Neoplasms | 1 | 2014 | 101 | 0.440 |
Why?
|
Data Collection | 2 | 2013 | 3329 | 0.430 |
Why?
|
Deoxycytidine | 4 | 2024 | 888 | 0.430 |
Why?
|
Self Care | 1 | 2018 | 798 | 0.430 |
Why?
|
Leucovorin | 6 | 2022 | 643 | 0.410 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2022 | 716 | 0.380 |
Why?
|
Esophageal Neoplasms | 4 | 2024 | 1676 | 0.360 |
Why?
|
Neoplasms | 11 | 2025 | 22386 | 0.350 |
Why?
|
Pancreatic Neoplasms | 7 | 2024 | 5442 | 0.340 |
Why?
|
Organoplatinum Compounds | 5 | 2019 | 408 | 0.320 |
Why?
|
Age Factors | 8 | 2025 | 18478 | 0.310 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10358 | 0.280 |
Why?
|
Stomach Neoplasms | 3 | 2024 | 1484 | 0.270 |
Why?
|
Aged, 80 and over | 18 | 2025 | 59680 | 0.260 |
Why?
|
Quality Improvement | 2 | 2018 | 3858 | 0.260 |
Why?
|
Patient Participation | 3 | 2020 | 1450 | 0.250 |
Why?
|
Aged | 36 | 2025 | 171520 | 0.240 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2020 | 423 | 0.230 |
Why?
|
Electronics | 2 | 2022 | 318 | 0.220 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11249 | 0.220 |
Why?
|
Neoplasm Metastasis | 6 | 2024 | 4931 | 0.210 |
Why?
|
Liver Neoplasms | 3 | 2014 | 4362 | 0.210 |
Why?
|
Research Design | 2 | 2022 | 6217 | 0.210 |
Why?
|
Middle Aged | 33 | 2025 | 223418 | 0.200 |
Why?
|
Humans | 62 | 2025 | 768451 | 0.200 |
Why?
|
Quality of Life | 6 | 2024 | 13497 | 0.200 |
Why?
|
Male | 38 | 2025 | 364781 | 0.200 |
Why?
|
Triazoles | 2 | 2020 | 905 | 0.190 |
Why?
|
Communication Barriers | 2 | 2022 | 419 | 0.190 |
Why?
|
Antineoplastic Agents | 6 | 2022 | 13708 | 0.190 |
Why?
|
Esophagogastric Junction | 2 | 2024 | 349 | 0.190 |
Why?
|
Disease-Free Survival | 9 | 2014 | 6856 | 0.180 |
Why?
|
Female | 38 | 2025 | 396943 | 0.180 |
Why?
|
Anus Neoplasms | 1 | 2024 | 338 | 0.170 |
Why?
|
Adult | 25 | 2025 | 223542 | 0.170 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 101 | 0.170 |
Why?
|
Patient Education as Topic | 2 | 2020 | 2339 | 0.150 |
Why?
|
Interleukin-1beta | 1 | 2024 | 1021 | 0.150 |
Why?
|
Patient Selection | 1 | 2010 | 4266 | 0.150 |
Why?
|
Neutropenia | 1 | 2023 | 892 | 0.150 |
Why?
|
Palliative Care | 4 | 2025 | 3644 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 2 | 2024 | 3237 | 0.140 |
Why?
|
Focus Groups | 2 | 2024 | 1448 | 0.140 |
Why?
|
Feasibility Studies | 3 | 2023 | 5308 | 0.130 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2018 | 219 | 0.130 |
Why?
|
Medical Oncology | 3 | 2023 | 2347 | 0.130 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2025 | 1097 | 0.120 |
Why?
|
Anemia, Myelophthisic | 1 | 2014 | 6 | 0.120 |
Why?
|
Prognosis | 8 | 2020 | 30028 | 0.120 |
Why?
|
Tumor Lysis Syndrome | 1 | 2014 | 38 | 0.120 |
Why?
|
Comorbidity | 2 | 2022 | 10601 | 0.110 |
Why?
|
Emigrants and Immigrants | 1 | 2020 | 548 | 0.110 |
Why?
|
Cholecalciferol | 1 | 2019 | 557 | 0.110 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 647 | 0.110 |
Why?
|
Receptor, erbB-2 | 1 | 2024 | 2586 | 0.110 |
Why?
|
Leukemia | 1 | 2022 | 1527 | 0.110 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2014 | 187 | 0.110 |
Why?
|
Tegafur | 1 | 2013 | 39 | 0.110 |
Why?
|
Life Expectancy | 1 | 2020 | 1249 | 0.110 |
Why?
|
Minority Groups | 1 | 2020 | 1215 | 0.110 |
Why?
|
Qualitative Research | 1 | 2024 | 3115 | 0.110 |
Why?
|
Smoking | 1 | 2010 | 9099 | 0.110 |
Why?
|
Phenylurea Compounds | 2 | 2013 | 532 | 0.100 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 167 | 0.100 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3939 | 0.100 |
Why?
|
Perception | 1 | 2018 | 1207 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2302 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1638 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2024 | 1755 | 0.100 |
Why?
|
Treatment Outcome | 11 | 2024 | 65409 | 0.100 |
Why?
|
Diabetic Retinopathy | 1 | 2020 | 1299 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2014 | 2331 | 0.090 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9507 | 0.090 |
Why?
|
CpG Islands | 1 | 2015 | 1209 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2010 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1638 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2023 | 2072 | 0.090 |
Why?
|
Informed Consent | 1 | 2017 | 1012 | 0.090 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 427 | 0.090 |
Why?
|
Food Hypersensitivity | 1 | 2018 | 737 | 0.080 |
Why?
|
Survival Rate | 3 | 2019 | 12875 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2014 | 1840 | 0.080 |
Why?
|
Software | 1 | 2023 | 4463 | 0.080 |
Why?
|
Patient-Centered Care | 1 | 2019 | 1439 | 0.080 |
Why?
|
Sirolimus | 2 | 2013 | 1542 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4083 | 0.070 |
Why?
|
Colectomy | 1 | 2013 | 700 | 0.070 |
Why?
|
Safety | 1 | 2012 | 1159 | 0.070 |
Why?
|
Quinolines | 1 | 2013 | 769 | 0.070 |
Why?
|
Neuroendocrine Tumors | 1 | 2013 | 649 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5909 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1376 | 0.070 |
Why?
|
Paclitaxel | 2 | 2024 | 1737 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2015 | 22293 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1349 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2019 | 3445 | 0.060 |
Why?
|
Survival Analysis | 2 | 2021 | 10125 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1628 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7451 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3267 | 0.060 |
Why?
|
Risk Assessment | 4 | 2020 | 24311 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8559 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5455 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 2228 | 0.060 |
Why?
|
Physicians | 2 | 2021 | 4615 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2019 | 4340 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2884 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5740 | 0.060 |
Why?
|
Mutation | 4 | 2023 | 30243 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5192 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 2067 | 0.060 |
Why?
|
Genetic Variation | 1 | 2018 | 6610 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2020 | 5342 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2013 | 6537 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3520 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 106 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 300 | 0.050 |
Why?
|
DNA Methylation | 1 | 2015 | 4421 | 0.050 |
Why?
|
Pyridines | 1 | 2013 | 2888 | 0.050 |
Why?
|
Administration, Oral | 1 | 2009 | 4041 | 0.050 |
Why?
|
Prospective Studies | 3 | 2024 | 54914 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 631 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2023 | 387 | 0.040 |
Why?
|
Multimedia | 1 | 2020 | 76 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 639 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12561 | 0.040 |
Why?
|
Sulfonamides | 1 | 2009 | 1988 | 0.040 |
Why?
|
Decision Making | 1 | 2013 | 3961 | 0.040 |
Why?
|
Pyrazoles | 1 | 2009 | 2024 | 0.040 |
Why?
|
Corylus | 1 | 2018 | 3 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 190 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2024 | 81834 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2014 | 10494 | 0.040 |
Why?
|
Penaeidae | 1 | 2018 | 22 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2010 | 2079 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 614 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2021 | 271 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6657 | 0.040 |
Why?
|
Databases, Factual | 1 | 2013 | 8081 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 819 | 0.040 |
Why?
|
Recurrence | 1 | 2010 | 8510 | 0.040 |
Why?
|
Age of Onset | 1 | 2024 | 3342 | 0.030 |
Why?
|
Pamphlets | 1 | 2017 | 71 | 0.030 |
Why?
|
Patients | 1 | 2023 | 909 | 0.030 |
Why?
|
Eggs | 1 | 2018 | 182 | 0.030 |
Why?
|
Culture | 1 | 2020 | 624 | 0.030 |
Why?
|
Odds Ratio | 2 | 2023 | 9687 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1855 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2024 | 1408 | 0.030 |
Why?
|
Death | 1 | 2020 | 683 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39430 | 0.030 |
Why?
|
Young Adult | 2 | 2021 | 60045 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 637 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2143 | 0.030 |
Why?
|
Milk | 1 | 2018 | 445 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 12450 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6527 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12096 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2020 | 2733 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5709 | 0.020 |
Why?
|
Adolescent | 3 | 2021 | 89168 | 0.020 |
Why?
|
Video Recording | 1 | 2017 | 974 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2010 | 9425 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1489 | 0.020 |
Why?
|
Language | 1 | 2020 | 1557 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8908 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 2930 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20762 | 0.020 |
Why?
|
Sex Factors | 1 | 2025 | 10647 | 0.020 |
Why?
|
Niacinamide | 1 | 2013 | 419 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2012 | 286 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4642 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2239 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2013 | 890 | 0.020 |
Why?
|
Patient Compliance | 1 | 2020 | 2696 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2039 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3771 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7213 | 0.020 |
Why?
|
Microsatellite Instability | 1 | 2013 | 726 | 0.020 |
Why?
|
Signal Transduction | 1 | 2013 | 23638 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1884 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8635 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1755 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 560 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 906 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2051 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2014 | 1078 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3708 | 0.020 |
Why?
|
ras Proteins | 1 | 2013 | 1058 | 0.020 |
Why?
|
Prevalence | 1 | 2025 | 15880 | 0.020 |
Why?
|
SEER Program | 1 | 2012 | 1476 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10784 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7863 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8051 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2611 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1307 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1766 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3311 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 5532 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6242 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22365 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2021 | 14766 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6091 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15965 | 0.010 |
Why?
|
Risk Factors | 1 | 2010 | 74915 | 0.010 |
Why?
|
Animals | 3 | 2023 | 169418 | 0.010 |
Why?
|
Mice | 2 | 2023 | 82045 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4534 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3611 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14158 | 0.010 |
Why?
|
United States | 2 | 2022 | 73121 | 0.010 |
Why?
|
Cohort Studies | 1 | 2022 | 41797 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7575 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15460 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12242 | 0.010 |
Why?
|
Disease Progression | 1 | 2013 | 13655 | 0.010 |
Why?
|
Medicare | 1 | 2012 | 6881 | 0.010 |
Why?
|